We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Molecular Assay Approved for Dengue Diagnosis

By LabMedica International staff writers
Posted on 16 Jul 2012
A molecular diagnostic test has been developed and officially approved to detect the dengue virus in people with symptoms of dengue or dengue hemorrhagic fever.

The DENV-1-4 Real Time Polymerase Chain Reaction (RT-PCR) Assay was developed by the US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) for use in the USA and can be conducted by using equipment and supplies that are already performed in many public health laboratories to diagnose influenza.

With the RT-PCR test, laboratories are now able to diagnose all four dengue virus types within the first seven days after the appearance of any dengue-related symptoms. This coincides with the time the majority of people generally take in order to visit a health care professional whilst the dengue virus may already be present in their blood. The test is the first molecular dengue test approved by the US Food and Drug Administration (FDA, Silver Springs, MD, USA), which detects the actual virus in comparison with other available FDA-approved tests, which just detect immunoglobin M (IgM) a certain type of antibody to the dengue virus.

Although the majority of patients start developing antibodies within four days after falling ill, the antibodies are not present in everyone until seven days after they have become infected dengue, which means that health care professionals cannot always recognize early enough that a person has become infected with dengue. Each year, thousands of US visitors develop dengue fever, which manifests itself through high fever, severe headaches or pain behind the eyes, aching joints, muscles, and bones, rash and mild bleeding of the nose or gums, as well as easy bruising. In severe cases, dengue can lead to hemorrhage, shock, and even death.

Jorge L. Munoz-Jordan, PhD, chief of the Molecular Diagnostics and Research at the CDC Dengue Branch, said "The need for the new dengue diagnostic test was high. Patients will be diagnosed sooner than before, and public health laboratories will have a clearer picture of the true number of dengue cases. Dengue is now a reportable disease in the United States, and the availability of state-of-the-art dengue diagnostics will improve patient management and the public health response to dengue." The DENV-1-4 RT-PCR Test kits will be available for distribution to clinical and public health laboratories in the USA and abroad from July 2, 2012.

Related Links:

US Centers for Disease Control and Prevention
US Food and Drug Administration



New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
Automated Blood Typing System
IH-500 NEXT
New
Silver Member
Benchtop Image Acquisition Device
Microwell Imager
New
Thyroxine ELISA
T4 ELISA

Latest Microbiology News

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Innovative Diagnostic Approach for Bacterial Infections to Enable Faster and Effective Treatment